TP53 Arg72Pro polymorphism is associated with increased overall survival but not response to therapy in Portuguese/Caucasian patients with advanced cervical cancer

• Type: Article in International Scientific Journal
• Date: 2018

Authors

Coelho, A (Author) Other; Nogueira, A (Author) Other; Soares, S (Author) Other; Assis, J (Author) Other; Pereira, D (Author) Other; Bravo, I (Author) Other; Catarino, R (Author) Other; Rui Medeiros (Author) ICBAS

Journal

Title: Oncology Letters

Vol. 15

Pages: 8165-8171

ISSN: 1792-1074

Publisher: Spandidos Publications

Indexing

ISI Web of Knowledge - 6 Citations

Scopus - 9 Citations

Other information

Authenticus ID: P-00N-TXC

DOI: 10.3892/ol.2018.8354

Abstract (EN): Identification of mechanisms that influence the therapeutic response and survival in patients with cancer is important. It is known that the genetic variability of the host, including presence of genetic polymorphisms in genes involved in DNA damage response, serves a crucial role in the prognosis of these patients. The present hospital-based retrospective cohort study aimed to evaluate the influence of TP53 Arg72Pro (rs1042522) polymorphism in the clinical outcome of 260 Caucasian patients diagnosed with cervical cancer and treated with concomitant radiotherapy and chemotherapy. The polymorphism genotyping was assessed using allelic discrimination by quantiative polymerase chain reaction. The results indicate that the TP53 Arg72Pro polymorphism did not significantly impact the response to therapy (P= 0.571) nor disease-free survival (P= 0.081). However, the polymorphism did influence overall survival, as increased median survival time was observed for patients carrying Arg/Pro genotype when compared with patients with Arg/Arg and Pro/Pro genotypes (126 months vs. 111 months, respectively; P= 0.047). To conclude, the present findings suggest that a pharmacogenomic profile based on the genetic background of patients, including the analysis of the TP53 genotypes, may individualize treatment nad assist in the selection of therapies that may improve clinical outcome and lower toxicity for the patients.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 7